Profund Advisors’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Profund Advisors’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-34,220	Closed	-$538K	–	1188
2024 Q1	$538K	Buy	34,220 +10,894	+47%	+$168K	0.02%	550
2023 Q4	$376K	Sell	23,326 -729	-3%	-$9.3K	0.02%	666
2023 Q3	$306K	Sell	24,055 -18,030	-43%	-$249K	0.02%	657
2023 Q2	$593K	Sell	42,085 -1,462	-3%	-$20.9K	0.03%	459
2023 Q1	$673K	Buy	+43,547	New	+$727K	0.04%	412

Other funds holding DCPH

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Profund Advisors's DCPH Position: Q2 2024 in Review

Profund Advisors sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 34,220 shares — an estimated $538K sold.

Profund Advisors first reported a position in DCPH in Q1 2023 and held it in 5 quarters. The position peaked at $673K in Q1 2023. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

Profund Advisors reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Profund Advisors sold 34,220 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $538K.
Profund Advisors first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 5 quarters.
Profund Advisors's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $673K in Q1 2023.
1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on Profund Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.